Reata Pharmaceuticals, Inc.
RETADrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bardoxolone Methyl | Phase 2 | Covid19 | - | - |
Frequently asked questions
What is in Reata Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Reata Pharmaceuticals, Inc.'s (RETA) pipeline across Phase 2. Its lead program is Bardoxolone Methyl (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Reata Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Reata Pharmaceuticals, Inc. (RETA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track RETA biotech catalysts?→
Add RETA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Reata Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.